Severity Index News Today

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

These data highlighted which drug, in combination with topical corticosteroids, produced the best efficacy results for those with atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.

FOR IMMEDIATE RELEASE Tokyo, May 31, 2024 Positive Top-line Results of Phase 3 Clinical Study of JTE-061 Cream, Aryl hydrocarbon Receptor ...

Results from two phase 3 trials showed that topical tapinarof, once a day, was effective and safe in patients with atopic dermatitis as young as 2 years old.

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all...

Consensus was reached during an in-person meeting attended by 34 individuals with diverse backgrounds.

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and a Worst Pruritus Numerical Rating Scale of 0 or 1.